Prostate cancer and androgenic alopecia

References

• Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control13(3), 158–168 (2006).
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 european countries: an overview. Eur. J. Cancer46, 3040–3052 (2010).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J. Natl Cancer Inst.95(12), 868–878 (2003).
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J. Natl Cancer Inst.101(6), 374–383 (2009).
   PubMedGoogle Scholar
• Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ. What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?. J. Clin. Oncol.29(4), 464–467 (2011).
   PubMedGoogle Scholar
• Lee TH, Kantoff PW, McNaughton-Collins MF. Screening for prostate cancer. N. Engl. J. Med.360, e18 (2009).
   Google Scholar
• Peinemann F, Grouven U, Hemkens LG et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev.7, CD00871 (2011).
   Google Scholar
• Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol. Nutr. Food Res.53, 171–184 (2009).
   PubMed Web of Science ®Google Scholar
• Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur. Urol.258(2), 275–280 (2010).
   Google Scholar
• Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med.358(9), 910–919 (2008).
   PubMed Web of Science ®Google Scholar
• Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J. Natl Cancer Inst.98(23), 1694–1706 (2006).
   PubMed Web of Science ®Google Scholar
• Edwards SM, Evans DG, Hope Q et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br. J. Cancer103(6), 918–924 (2010).
   PubMed Web of Science ®Google Scholar
• Mitra AV, Bancroft EK, Barbachano Y et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int.107(1), 28–39 (2011).
   PubMed Web of Science ®Google Scholar
• Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J. Investig. Dermatol. Symp. Proc.10, 184–189 (2005).
   PubMedGoogle Scholar
• Cash J, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J. Am. Acad. Dermatol.29(4), 568–575 (1993).
   PubMed Web of Science ®Google Scholar
• Cash TF. Losing hair, losing points?. The effects of male pattern baldness on social impression formation. J. Appl. Soc. Psychol.20, 154–167 (1990).
   Web of Science ®Google Scholar
• Dogramaci AC, Balci DD, Balci A et al. Is androgenetic alopecia a risk for atherosclerosis?. J. Eur. Acad. Dermatol. Venereol.23, 673–677 (2009).
   PubMed Web of Science ®Google Scholar
• Su LH, Hsiu-His Chen T. Association of androgenetic alopecia with metabolic syndrome in men: a community-based survey. Br. J. Dermatol.163, 371–377 (2010).
   PubMed Web of Science ®Google Scholar
• Matilainen VA, Mäkinen PK, Keinänen-Kiukaanniemi SM. Early onset of androgenetic alopecia associated with early severe coronary heart disease: a population-based, case–control study. J. Cardiovasc. Risk.8(3), 147–151 (2001).
   PubMedGoogle Scholar
• Paus R, Cotsarelis G. The biology of hair follicles. N. Engl. J. Med.341(7), 491–497 (1999).
   PubMed Web of Science ®Google Scholar
• Brockschmidt FF, Heilmann S, Ellis JA et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br. J. Dermatol.165(6), 1293–1302 (2011).
   PubMed Web of Science ®Google Scholar
• Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev. Mol. Med.4(22), 1–11 (2002).
   Google Scholar
• Norwood OT. Male pattern baldness: classification and incidence. South Med. J.68, 1359–1365 (1975).
   PubMed Web of Science ®Google Scholar
• Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, Trichopoulos D. Risk factors for prostate cancer: a case–control study in Greece. Int. J. Cancer80(5), 699–703 (1999).
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Lesko SM, Conaway MR et al. Serum androgens: associations with prostate cancer risk and hair patterning. J. Androl.18(5), 495–500 (1997).
   PubMedGoogle Scholar
• Giles GG, Severi G, Sinclair R et al. Androgenetic alopecia and prostate cancer: findings from an Australian case–control study. Cancer Epidemiol. Biomarkers Prev.11(6), 549–553 (2002).
   PubMed Web of Science ®Google Scholar
• Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev.9(5), 523–527 (2000).
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Schildkraut JM, Thompson D et al. Early onset baldness and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev.9(3), 325–328 (2000).
   PubMedGoogle Scholar
• Yassa M, Saliou M, De Rycke Y et al. Male pattern baldness and the risk of prostate cancer. Ann. Oncol.22(8), 1824–1827 (2011).
   PubMed Web of Science ®Google Scholar
• Cremers RG, Aben KK, Vermeulen SH, den Heijer M, van Oort IM, Kiemeney LA. Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur. J. Cancer46(18), 3294–3299 (2010).
   PubMedGoogle Scholar
• Wright JL, Page ST, Lin DW, Stanford JL. Male pattern baldness and prostate cancer risk in a population-based case–control study. Cancer Epidemiol.34, 131–135 (2010).
   PubMedGoogle Scholar
• Lattouf JB, Srinivasan R, Pointo PA, Linehan WM, Neckers L. Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat. Clin. Pract. Urol.3, 590–601 (2006).
   PubMedGoogle Scholar
• Zhu YS, Imperato-McGinley JL. 5α-reductase isozymes and androgen actions in the prostate. Ann. NY Acad. Sci.1155, 43–56 (2009).
   PubMed Web of Science ®Google Scholar
• Randall VA. Androgens and hair growth. Dermatol. Ther.21(5), 314–328 (2008).
   PubMed Web of Science ®Google Scholar
• Hamilton JB. Male hormone is a prerequisite and an incitant in common baldness. Am. J. Anat.71, 451–480 (1942).
   Google Scholar
• Kaufman KD, Olsen EA, Whiting D et al. Finasteride in the treatment of men with androgenetic alopecia. J. Am. Acad. Dermatol.39, 578–589 (1998).
   PubMed Web of Science ®Google Scholar
• Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J. Invest. Dermatol.109, 296–300 (1997).
   PubMed Web of Science ®Google Scholar
• Yeap BB. Testosterone and ill-health in aging men. Nat. Clin. Pract. Endocrinol. Metab.5, 113–121 (2009).
   PubMedGoogle Scholar
• Chadha KC, Nair BB, Chakravarthi S et al. Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities. Prostate71(15), 1680–1690 (2011).
   PubMedGoogle Scholar
• Heinlen CA, Chang C. Androgen receptor in prostate cancer. Endocrine Rev.25, 276–308 (2004).
   PubMedGoogle Scholar
• Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol.59(4), 572–583 (2011).
   PubMed Web of Science ®Google Scholar
• Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch. Dermatol.146(10), 1141–1150 (2010).
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Savage CJ, Lilja H. Finasteride to prevent prostate cancer: Should all men or only a high-risk subgroup be treated?. J. Clin. Oncol.28(7), 1112–1116 (2010).
   PubMedGoogle Scholar
• Kabai P. Androgenic alopecia may have evolved to protect men from prostate cancer by increasing skin exposure to ultraviolet radiation. Med. Hypotheses70(5), 1038–1040 (2008).
   PubMedGoogle Scholar
• Hayes VM, Severi G, Padilla EJ et al. 5alpha-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int. J. Cancer120(4), 776–780 (2007).
   PubMed Web of Science ®Google Scholar
• Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev.12, 618–624 (2003).
   PubMedGoogle Scholar